Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.

Carrillo JF, Vázquez-Romo R, Ramírez-Ortega MC, Carrillo LC, Gómez-Argumosa E, Oñate-Ocaña LF.

Front Endocrinol (Lausanne). 2019 Oct 29;10:737. doi: 10.3389/fendo.2019.00737. eCollection 2019.

2.

A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population.

Millan Catalan O, Campos-Parra AD, Vázquez-Romo R, Cantú de León D, Jacobo-Herrera N, Morales-González F, López-Camarillo C, Rodríguez-Dorantes M, López-Urrutia E, Pérez-Plasencia C.

Cancers (Basel). 2019 Aug 26;11(9). pii: E1246. doi: 10.3390/cancers11091246.

3.

miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.

Martinez-Gutierrez AD, Catalan OM, Vázquez-Romo R, Porras Reyes FI, Alvarado-Miranda A, Lara Medina F, Bargallo-Rocha JE, Orozco Moreno LT, Cantú De León D, Herrera LA, López-Camarillo C, Pérez-Plasencia C, Campos-Parra AD.

Int J Mol Med. 2019 Oct;44(4):1267-1280. doi: 10.3892/ijmm.2019.4292. Epub 2019 Jul 30.

4.

[Breast osteosarcoma originating in a phyllodes tumor. Report of one case].

Nieto-Coronel T, Salazar-Campos JE, León DC, Díaz-Molina R, Vázquez-Romo R, Bargalló-Rocha E.

Rev Med Chil. 2017 Aug;145(8):1076-1082. doi: 10.4067/s0034-98872017000801076. Spanish.

5.

The impact of the use of intraoperative radiotherapy on costs, travel time and distance for women with breast cancer in the Mexico City Metropolitan Area.

Bargallo-Rocha JE, Soto-Perez-de-Celis E, Picó-Guzmán FJ, Quintero-Rodríguez CE, Almog D, Santiago-Concha G, Flores-Balcazar CH, Corona J, Vazquez-Romo R, Villarreal-Garza C, Mohar A.

J Surg Oncol. 2017 Nov;116(6):683-689. doi: 10.1002/jso.24712. Epub 2017 Jun 12.

PMID:
28608393
6.

Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.

Campos-Parra AD, Mitznahuatl GC, Pedroza-Torres A, Romo RV, Reyes FIP, López-Urrutia E, Pérez-Plasencia C.

Int J Mol Sci. 2017 Jun 2;18(6). pii: E1182. doi: 10.3390/ijms18061182. Review.

7.

MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review).

González-Quintana V, Palma-Berré L, Campos-Parra AD, López-Urrutia E, Peralta-Zaragoza O, Vazquez-Romo R, Pérez-Plasencia C.

Oncol Rep. 2016 Jan;35(1):3-12. doi: 10.3892/or.2015.4369. Epub 2015 Oct 30. Review.

PMID:
26530778
8.

Transcript profiling distinguishes complete treatment responders with locally advanced cervical cancer.

Fernandez-Retana J, Lasa-Gonsebatt F, Lopez-Urrutia E, Coronel-Martínez J, Cantu De Leon D, Jacobo-Herrera N, Peralta-Zaragoza O, Perez-Montiel D, Reynoso-Noveron N, Vazquez-Romo R, Perez-Plasencia C.

Transl Oncol. 2015 Apr;8(2):77-84. doi: 10.1016/j.tranon.2015.01.003.

9.

Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors.

Barquet-Muñoz SA, Villarreal-Colin SP, Herrera-Montalvo LA, Soto-Reyes E, Pérez-Plasencia C, Coronel-Martínez J, Pérez-Montiel D, Vázquez-Romo R, Cantú de León D.

BMC Cancer. 2015 Feb 20;15:75. doi: 10.1186/s12885-015-1079-2.

10.

Cost-effectiveness of the 21-gene breast cancer assay in Mexico.

Bargalló-Rocha JE, Lara-Medina F, Pérez-Sánchez V, Vázquez-Romo R, Villarreal-Garza C, Martínez-Said H, Shaw-Dulin RJ, Mohar-Betancourt A, Hunt B, Plun-Favreau J, Valentine WJ.

Adv Ther. 2015 Mar;32(3):239-53. doi: 10.1007/s12325-015-0190-8. Epub 2015 Mar 5.

PMID:
25740550

Supplemental Content

Loading ...
Support Center